Orphan drugs revisited: Cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 2, 2015, Pages 331-340

  Brosa, Max ^a   García Del Muro, Xavier ^b   Mora, Jaume ^c   Villacampa, Alba ^a   Pozo Rubio, Tamara ^d   Cubells, Laia ^d   Montoto, Carmen ^d  

^a Oblikue Consulting SL   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

^d AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

cost effectiveness; mifamurtide; orphan drug; osteosarcoma; pharmacoeconomics; QALY

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; BORTEZOMIB; ECULIZUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIGLUCERASE; INTERFERON; LARONIDASE; LENALIDOMIDE; LEXIDRONAM SAMARIUM SM 153; MIFAMURTIDE; MURAMYL DIPEPTIDE DERIVATIVE; MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE; ORPHAN DRUG; PLACEBO; RADIUM CHLORIDE RA 223; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; PHOSPHATIDYLETHANOLAMINE;

ADD ON THERAPY; ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BONE METASTASIS; BUDGET; CANCER CHEMOTHERAPY; CANCER GRADING; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ECONOMIC EVALUATION; FABRY DISEASE; GASTROINTESTINAL STROMAL TUMOR; GAUCHER DISEASE; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; HURLER SYNDROME; KIDNEY CARCINOMA; MORTALITY; MULTIPLE MYELOMA; NATIONAL HEALTH SERVICE; NONHUMAN; OSTEOSARCOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SPAIN; ADOLESCENT; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; CHILD; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; ECONOMICS; FEMALE; INFANT; MALE; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; PROBABILITY; YOUNG ADULT;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; MALE; MARKOV CHAINS; ORPHAN DRUG PRODUCTION; OSTEOSARCOMA; PHOSPHATIDYLETHANOLAMINES; QUALITY-ADJUSTED LIFE YEARS; SPAIN; YOUNG ADULT;

EID: 84924602142     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.972378     Document Type: Article

References (44)

1. European Medicines Agency (EMA). Human medicines - Mepact (mifamurtide). [Updated 6 September 2012]. Available from: www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000802/human-med-000899. jsp&mid=WC0b01ac058001d12
2. Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, et al. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer 2006;42(13): 2183-90
3. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Childrens Oncology Group. J Clin Oncol 2008;26(4): 633-8
4. National Cancer Institute (NCI). Osteosarcoma and malignant fibrous histiocytoma of bone treatment. Available from: www.cancer.gov/cancertopics/pdq/treatment/osteosarcoma [Last accessed 2009]
5. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007;2:6
6. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009; 125(1):229-34
7. Peris Bonet R, et al. Cáncer infantile en España. Estadísticas 1980-2011. In: Registro Nacional de Tumores Infantiles (RNTISEHOP). Universitat de València; Ed Valencia: 2012
8. Geraci M, Birch JM, Alston RD, et al. Cancer mortality in 13 to 29-year-olds in England and Wales, 1981-2005. Br J Cancer 2007;97(11):1588-94
9. World Health Organisation (WHO). Global Health Observatory/WHOSIS. Available from: www.who.int/whosis/mort/download/en/index.html [Last accessed 2009]
10. Longhi A, Errani C, De PM, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32(6): 423-36
11. Automated Childhood Cancer Information System. Osteosarcoma incidence and survival by registry and tumour. Available from: www-dep.iarc.fr/accis/data.htm [Last accessed 2009]
12. Wilkins RM, Cullen JW, Odom L, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 2003;10(5): 498-507
13. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23(9):2004-11
14. Redondo A, Cruz J, Lopez-Pousa A, Barón F. SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013. Clin Transl Oncol 2013;15(12):1037-43
15. Brosa M, Gisbert R, Rodríguez JM y Soto J. Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario. Pharmacoeconomics Spanish Res Articles 2005;2(2):64-78
16. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003;21(4):710-15
17. López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11(5):513-20
18. National Institute for Health and Clinical Excellence. Discounting of health benefits in special circumstances. Available from: www. nice.org.uk/media/955/4F/Clarification-to-section-5.6-of-the-Guide-to-Methods-of-Technology-Appraisals.pdf
19. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009;152: 3-13
20. Real Decreto Ley 8/2010 de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit Mifamurtide & osteosarcoma: economic point of view Research Report informahealthcare.com 339 público In: Boletín oficial del estado. 126: 45070-128.Spain: 2010
21. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154-8
22. Jeys LM, Grimer RJ, Carter SR, et al. Post operative infection and increased survival in osteosarcoma patients: are they associated?. Ann Surg Oncol 2007;14(10):2887-95
23. MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. J Natl Can Inst 1989;81:935-8
24. Schulz G, Cheresh DA, Varki NM, et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44(12 Pt 1):5914-20
25. Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 2010;10(2):200-9
26. Yu AL, Gilman AL, Ozkaynak MF, et al. Childrens Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363(14):1324-34
27. Park JR, Bagatell R, London WB, COG Neuroblastoma Committee. Childrens Oncology Groups 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013;60(6):985-93
28. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264-70
29. National Institute for Health and Clinical Excellence. Appraising Orphan Drugs. Available from: www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf
30. Ministerio de Sanidad y Política Social (MSPS). El Ministerio de Sanidad y Consumo incluye en la financiación pública dos nuevos medicamentos para enfermedades raras. Available from: www. msps.es/gabinetePrensa/notaPrensa/desarrolloNotaPrensa.jsp?id=1421
31. European Medicines Agency (EMA). Medicines for rare diseases, 2011. Available at www.ema.europa.eu/ema/index.jsp?. curl=pages/special-topics/general/general-content-000034.jsp&mid=WC0b01ac058002d4eb
32. Orofino J, Soto J, Casado MA, Oyagüez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy 2010;8(5):301-15
33. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99(2):112-28
34. Instituto Nacional de Estadística - INE. Tablas de mortalidad de la población de España 1991-2008. Available from: www. ine.es/jaxi/tabla.do?path=/t20/p319a/serie/l0/&file=01001.px&type=pcaxis&L=0 [Last accessed 17 June 2010]
35. CGCOF (Consejo General del Colegio Oficial de Farmacéuticos) 2011. Available from: www.portalfarma.com [Last accessed December 2011]
36. E-Salud. Base de datos de costes sanitarios españoles (2011). Oblikue Consulting. Available from: www.oblikue.com/bddcostes/ [Last accessed December 2011]
37. Ministerio de sanidad, política social e igualdad. Portal estadístico. Available from: www.msps.es/estadEstudios/estadisticas/sisInfSanSNS/home.htm [Last accessed December 2011]
38. Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. BMJ 2005;331(7523):1019-21
39. Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation ther-Apy for severe alpha1-Antitrypsin deficiency. Am J Respir Crit Care Med 2003;167(10):1387-92
40. García Quetglas E, Azanza Perea JR, Lecumberri Villame-diana R. New therapeutic strategies for Mieloma múltiple. Efficacy and cost-effectiveness analyses. Med Clin (Barc) 2008;130(16):626-35
41. Cannock M, Wang D, Fry-Smith A, Moore D. Prevalence and prognosis of paroxysmal nocturnal haemoglobinurea and the clinical and cost-effectiveness of eculizumab [Report Number 69]. Birmingham (UK): University of Birmingham; 2008. Available from: www. rep.bham.ac.uk/2008/PNH.pdf
42. Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of temsiro-limus for first line treatment of advanced renal cell carcinoma. Value Health 2010;13(1):61-8
43. Paz-Ares L, García del Muro X, Grande E, et al. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumors (GIST) after progression or intolerance with imatinib. Clin Transl Oncol 2008;10(12): 831-9
44. Maroto P, Villavicencio H, Piñol C, et al. Análisis coste-efectividad de sorafenib oral en el tratamiento del carcinoma de células renales avanzado. Rev Esp Econ Salud 2008;7(4):173-80